Core Insights - The "bald economy" sector is gaining attention as Mandi Inc., a subsidiary of Sihuan Pharmaceutical, has submitted its IPO application to list on the Hong Kong Stock Exchange, aiming to become the first publicly listed company in China's hair health sector [2] - Mandi Inc. is backed by a rigid demand from over 339 million people suffering from hair loss and a market projected to grow at a compound annual growth rate (CAGR) of 11.3%, reaching a market size of 171.4 billion yuan by 2035 [3][4] - Despite strong performance and market potential, Mandi Inc. faces challenges such as over-reliance on core products, insufficient R&D investment, and high supply chain concentration [6][7] Market Dynamics - The hair health market in China is experiencing explosive growth, with the number of hair loss sufferers expected to reach 339 million by 2024, predominantly among individuals under 35 years old [3] - The market for hair health management is projected to exceed 80 billion yuan in 2024, with a sustained CAGR of 11.3% from 2024 to 2035 [3] - Mandi Inc. has established a strong competitive position, with its core product line, including the Mandi® series, holding over 70% market share in the hair loss treatment sector [4] Financial Performance - Mandi Inc.'s revenue grew from 982 million yuan in 2022 to 1.455 billion yuan in 2024, with net profit increasing from 202 million yuan to 390 million yuan during the same period, reflecting a CAGR of 21.7% [4][5] - The gross profit margin has remained stable above 80%, reaching 82.7% in 2024, significantly higher than the industry average [4] Challenges and Risks - Mandi Inc. heavily relies on its core product line, with 92.4% of its revenue in the first half of 2025 coming from the Mandi series, indicating vulnerability to market changes [6][7] - The company has low R&D investment, with only 2.62% of revenue allocated to R&D in the first half of 2025, raising concerns about long-term competitiveness [7] - High concentration in the supply chain, with the top five suppliers accounting for 75.6% of procurement, poses risks to production stability and cost control [7] Strategic Plans - Mandi Inc. plans to use IPO proceeds to enhance R&D, expand its product pipeline, and optimize its supply chain, focusing on female hair loss treatments and new topical formulations [8] - The company aims to balance sales and R&D investments to build long-term technological barriers while accelerating new product iterations to reduce dependence on the Mandi series [8] - The competitive landscape is shifting towards technology and brand competition, necessitating Mandi Inc. to maintain its market share amidst increasing competition from traditional pharmaceutical companies and emerging brands [8][9]

Core Viewpoint - The launch of the Hang Seng Biotechnology Index futures on November 28 is expected to provide investors with new risk hedging tools and enhance liquidity in the biotechnology sector [1] Group 1: Index and Market Overview - The Hang Seng Biotechnology Index was launched by Hang Seng Indexes Company in 2019 to reflect the overall performance of the biotechnology sector in the Hong Kong stock market [1] - The index currently includes notable companies such as Innovent Biologics, BeiGene, WuXi Biologics, CanSino Biologics, and 3SBio, covering sub-sectors like CXO and innovative drugs [1] Group 2: Market Trends and Expectations - The introduction of the index futures is anticipated to attract foreign capital back to the biotechnology sector amid a global liquidity easing cycle initiated by the Federal Reserve's interest rate cuts [1] - The continuous inflow of southbound funds is expected to create a resonance effect, further boosting the biotechnology sector in the Hong Kong market [1]

Group 1: Market Overview - The Hong Kong stock market experienced a rebound, with the Hang Seng Index rising by 1.97%, the Hang Seng China Enterprises Index increasing by 1.79%, and the Hang Seng Tech Index climbing by 2.78% [2] - Northbound capital saw a net inflow of HKD 8.571 billion, with Alibaba, Tencent, and Kuaishou being the most actively traded stocks [2] - The technology sector showed significant growth, driven by positive news from various tech companies, including Alibaba's AI assistant app surpassing 10 million downloads in its first week [3][4] Group 2: Company Analysis - Haiwei Co., Ltd. - Haiwei Co., Ltd. is a leader in China's capacitor film market, established in 2006, with a market share of 10.9% in capacitor base films as of 2024 [7] - Revenue projections for Haiwei are expected to reach RMB 330 million in 2024, with a net profit of RMB 86.42 million, despite a slight decline in early 2025 [7] - The company benefits from strong R&D capabilities, a diversified product portfolio, and an experienced management team [9] Group 3: Industry Outlook - The Chinese capacitor base film market is projected to grow at a CAGR of 19.7%, increasing from 46,000 tons in 2019 to 113,000 tons by 2024, and expected to reach 224,000 tons by 2029 [8] - The market for capacitor base films used in electric vehicles is anticipated to grow from 48,000 tons in 2025 to 87,000 tons by 2029, with a CAGR of 16.2% [8] - The market for capacitor base films in new energy power systems is expected to grow from 34,000 tons in 2025 to 80,000 tons by 2029, with a CAGR of 23.6% [8]

策 略 定 期 报 告 2、根据科睿唯安《风起云涌：中国生物医药创新 2.0 时代》报告， 中国生物医药产业已进入以源头创新和全球竞争力为核心的 2.0 阶段。 2024 年中国跃居全球第二大新药首发市场，66%全球新活性化合物已 在中国上市，凸显深度全球接轨。截至 8 月份，2025 年对外许可交易 额达 500 亿美元，热点从 ADC 转向双抗/小分子等方向，创新价值获 国际认可。政策端形成从30天临床快审到商保目录的端到端支持体系。 企业层面，在研管线、专利及临床试验数量均实现同比超 100%增长， 展现强劲创新动能。面对新周期，产业正通过聚焦管线结构、强化数 据整合与先进技术应用，推动研发效率提升与成本优化，持续塑造"中 国智造"全球影响力。 团队成员 华福证券 2025 年 11 月 25 日 策 略 研 究 中国生物医药创新 2.0：全球竞合、技术驱动与战 略重塑（2025.11.17—2025.11.21） 投资要点： 近期观点 1、医药指数本周关注的 6 个子行业均为负收益，表现不佳。 技术研发不及预期；宏观需求变化；地缘政治影响 证 券 研 究 报 告 诚信专业 发现价值 1 请务必阅读报告 ...

环球市场动态 " 十 五 五 " 辅 导 读 本 中 的 增 量 信 息 股 票 新一轮美联储官员发声较为鸽派， 美联储 12 月降息预期回升，全球 市场周一回暖。A 股小幅上涨，市 场继续关注中日紧张关系；港股止 跌，科技股反弹明显；欧洲股市收 高，俄乌和谈取得进展进一步提振 市场；美股大幅反弹，科技股上涨 明显推动纳指涨 2.7%，金龙中国指 数同样大涨。 外 汇 / 商 品 交易员权衡乌克兰与俄罗斯达成和 平协议的前景，周一国际油价漲超 1%；美联储 12 月降息预期升温， 国际金价格上涨 0.4%。 固 定 收 益 周一美国国债上涨，长端领涨。美 联储官员再放鸽。市场上调对美联 储 12 月降息预期。2 年期美国国债 拍卖表现良好。亚洲债市交投清淡， 但表现稳健。 产品及投资方案部 注：bp/bps=基点；pt/pts=百分点 中信证券财富管理 (香港) 免责声明请参考封底 2025 年 11 月 25 日 ▪ 中央印发两本 "十五五" 辅导书籍，在经济增速方面，辅导书籍就 2035 远景目标所需的经济增速给出具体指 引，其中暗含引导物价回升或汇率在未来适度升值的诉求。在宏观政策方面，辅导书籍透露财政 ...

Core Insights - The article highlights the significant growth potential in the hair loss treatment market, particularly through the upcoming IPO of Mandi International, a subsidiary of Sangfor Pharmaceutical, which is set to capitalize on the booming demand for hair restoration products [1][20]. Market Overview - The hair loss market in China is experiencing explosive growth, with the number of affected individuals exceeding 339 million by 2024, translating to one in four people suffering from hair loss, predominantly among the younger demographic [4]. - The hair health management market is projected to grow from 52.7 billion RMB in 2024 to 171.4 billion RMB by 2035, with a compound annual growth rate (CAGR) of 11.3% [4]. Company Performance - Mandi International holds a 57% market share in the hair loss medication sector, with revenue expected to grow from 982 million RMB in 2022 to 1.455 billion RMB in 2024, reflecting a CAGR of 21.7% [1][12]. - The company's flagship product, Minoxidil, has seen a decline in sales, while the newly launched Minoxidil foam is driving growth, achieving sales of 283 million RMB in the first half of 2025, a 338% increase year-on-year [6][8]. Financial Metrics - Mandi's gross profit margin remains high, consistently above 80%, with net profits rising from 202 million RMB in 2022 to 390 million RMB in 2024 [9][12]. - The company has distributed 1.42 billion RMB in dividends to shareholders from 2022 to mid-2025, indicating strong cash flow management despite a decrease in asset value [20]. Competitive Landscape - Mandi International is facing increasing competition in the hair loss treatment market, with a need to diversify its product offerings beyond hair restoration to maintain growth [8][9]. - The company is also exploring new markets in skin health and weight management, although these segments are still in early development stages [9]. Family Business Background - The Lou family, founders of Sangfor Pharmaceutical, have established a significant presence in the capital markets with three listed companies, including Mandi International, which represents a strategic shift towards consumer healthcare [20][21]. - The family's wealth has been recognized, ranking them among the top in the biopharmaceutical sector, with a net worth of 15 billion RMB as of October 2025 [22][23].

Group 1: Market Overview - The US stock market saw all three major indices rise, with the Dow Jones up 0.44%, S&P 500 increasing by 1.5%, and Nasdaq gaining 2.69% [4] - The Hong Kong stock market also performed well, with the Hang Seng Index rising by 1.97% and the Hang Seng Tech Index up 2.78%, driven by strong performances in technology and automotive stocks [5] - A-shares in China experienced a collective increase, with the Shanghai Composite Index up 0.05%, Shenzhen Component Index up 0.37%, and ChiNext Index up 0.31%, despite a decrease in trading volume [6] Group 2: Commodity Prices - Gold prices rose significantly, closing at $4,134.79 per ounce, up 1.69%, while silver increased by 2.64% to $51.36 per ounce [7] - Crude oil prices also saw gains, with WTI crude closing at $58.89 per barrel, up 1.67%, and Brent crude at $62.79 per barrel, up 1.39% [7] Group 3: Economic Indicators - The Federal Reserve officials expressed support for a potential interest rate cut in December, with probabilities rising to 80% for a rate decrease [11] - The Chinese central bank announced a 10,000 billion yuan MLF operation scheduled for November 25, indicating ongoing monetary policy support [13]

Investment Rating - The report does not explicitly state an investment rating for the industry [2] Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 6.88% from November 17 to November 21, underperforming compared to the Wind All A index (-5.13%) and the CSI 300 index (-3.77%) [3][8] - All sub-sectors within the industry reported losses, with raw materials (-8.6%), offline pharmacies (-8.58%), and other biological products (-7.99%) leading the decline [3][8] - Major companies in the IVD sector are increasingly investing in cancer early screening, with Abbott announcing a $21 billion acquisition of Exact Sciences and Roche entering a partnership with Freenome valued at over $200 million [3][12] - Flu activity is on the rise, with the percentage of flu-like illness cases reported in southern provinces reaching 6.7%, up from 5.5% the previous week, and higher than the same period in previous years [3][11] Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector fell by 6.88%, underperforming the broader market indices [8] - All sub-sectors declined, with raw materials and offline pharmacies showing the largest drops [8] - Individual stock performances varied, with Hainan Haiyao increasing by 23.8% while Jindike fell by 25.5% [11] Industry News and Key Company Announcements Important Industry Events - The report highlights the increase in flu cases in both southern and northern provinces, surpassing levels from previous years [11] Industry News - GE HealthCare announced a $2.3 billion acquisition of Intelerad, indicating a focus on cloud and AI solutions in healthcare [12] - Significant acquisitions and partnerships in the cancer diagnostics space were noted, including Abbott's acquisition of Exact Sciences and Roche's collaboration with Freenome [12][15] Company Announcements - Various companies announced significant developments, including clinical trial approvals and new drug applications, reflecting ongoing innovation in the sector [15][16]

Market Overview - A-shares showed a rebound on November 24, with all three major indices closing in the green and over 4,200 stocks rising. However, market sentiment has slightly declined, with a trading volume of 1.74 trillion yuan, down by 2.4 billion yuan compared to the previous day [1] Sector Performance - The technology growth sector significantly recovered, with the defense and military industry emerging as a leading "super dark horse," attracting over 13.3 billion yuan in net inflows, the highest across all industries [2][4] - The defense military ETF (512810) surged by 3.78%, marking its largest single-day increase since July, while the general aviation ETF (159231) rose by 3.43%, both achieving their highest daily trading volumes in months [2][4] - The financial technology sector rebounded in the afternoon, with the largest financial technology ETF (159851) gaining 2% and maintaining its position above the annual line. The AI application by Alibaba, "Qianwen," achieved over 10 million downloads in just seven days, setting a record for AI application growth [3][14] Investment Insights - Analysts from Guotai Junan Securities believe that the Chinese stock market will gradually stabilize and embark on a year-end rally, despite recent global market fluctuations [4] - The defense military sector is expected to see increased investment due to ongoing geopolitical tensions, which may drive high-quality development in the industry [7] - The Hong Kong AI sector is showing strong momentum, with major stocks like Alibaba and Kuaishou experiencing significant gains, indicating a recovery phase for the sector [10][12] ETF Highlights - The Hong Kong Internet ETF (513770) has a current price-to-earnings ratio of 21.93, placing it in the historical bottom range, indicating a valuation advantage compared to other indices [10][11] - The financial technology ETF (159851) has a scale exceeding 90 billion yuan, with an average daily trading volume of 8 billion yuan over the past six months, making it a leading choice among similar ETFs [17]

【导读】港股三大指数大涨，AI概念股集体上攻 首先，千问App的底层技术支撑是阿里通义千问（Qwen）大模型。据了解，Qwen系列模型自2023年起便通过开源策略，在全球技术社区积累了广泛影响 力，累计下载量已突破6亿次，其性能也获得了包括英伟达CEO黄仁勋等的公开认可。其次，千问App精准定位为"会聊天能办事的个人AI助手"，强调其 实用价值。 创新药涨幅居前 11月24日，创新药概念股涨幅居前，三生制药涨6.07%，恒瑞医药涨5.61%，翰森制药涨5.29%，药明康德涨5.12%。 中国银河证券表示，看好2026年医药行业投资机会，近期震荡调整后估值已回落至相对低位，有望在2026年重启升势。投资思路上，寻找医药硬科技和细 分赛道超额收益。推荐关注创新药、创新器械（影像、高值耗材、消费器械等）、医疗AI等方向，关注医药消费复苏及独立第三方临床实验室（ICL）等 方向。 11月24日，港股三大指数集体大涨。截至收盘，恒生指数涨1.97%，报收于25716.50点；恒生国企指数涨1.79%，报收于9079.42点；恒生科技指数涨 2.78%，报收于5545.56点。全日大市成交额为3026亿港元，南向资金净买 ...